Sareum - Specialists in Cancer Drug Discovery
Print the page Smaller text Larger text

 

Issue of Options & Transfer of Shares
13 March, 2012

Research Update
27 February, 2012

Half-Yearly Report
27 February, 2012

Notice of Results
30 January, 2012

Result of AGM
14 December, 2011

RSS news feed News feed
requires RSS news reader

Sareum Holdings
Last Trading 0.77
Trade Time 15:43am
Change -0.08
Open 0.80
Day's Range 0.70 - 0.862
Volume 3924017

 

Sareum's small molecule drug discovery expertise is building value by developing drug candidates, focused on cancer and auto-immune disease, for licencing to pharmaceutical and biotechnology companies

 

Providing protein structure-based research services to accelerate customers’ drug discovery programmes
Developing oncology drug candidates for licensing to pharmaceutical companies

 

Learn more about Sareum’s pipeline of targeted small molecule drug candidates

Dr Tim Mitchell, CEO and co-founder of Sareum, discusses the Company's business model, its "SKIL®" technology platform and the progress in its drug research pipeline in this video presentation.

Sareum Holdings Plc's house broker, Hybridan LLP, will from time to time publish research notes on the Company. You can download the research notes from this page. (Latest update: Feb 2012).

2011 Annual Report & Accounts is available for download here: Annual Report 2011

Website last updated on: 5-March-2012

 

 


Requires RSS news reader

Requires MS Word

Requires Adobe Acrobat Reader


site map

email: info@sareum.co.uk tel: +44 (0) 1223 497700 fax: +44 (0) 1223 497701